Press Releases Ypsomed Group

Burgdorf – Ypsomed is recording weaker growth in the insulin pump business and is adjusting its approval strategy with the American FDA. In addition, Ypsomed is reducing its EBIT outlook for the current financial year 2019/20 to CHF 9 million due to one-time and temporary effects. Ypsomed confirms its mid-term EBIT target of CHF 100 million.

Montréal, Canada - The Ministry of Health of the Canadian Ontario region has added the YpsoPump® insulin pump to its list of approved devices funded by the Assistive Device Program (ADP). As of 13 January 2020, the YpsoPump® is officially reimbursed in the Ontario region and can be prescribed by health care professionals to people with diabetes that qualify for insulin pump therapy under the ADP.

Market entry of YpsoMate autoinjector for Teribone™ in Japan
Teribone™ autoinjector

Press Releases Ypsomed Group

Burgdorf – Terumo Corporation (Terumo), a leading global manufacturer and distributor of medical devices, will fill its PLAJEX™ syringe with the drug Teribone™ and assemble it with the YpsoMate prefilled autoinjector from Ypsomed. Teribone™ is a Teriparatide for the treatment of osteoporosis. The drug was developed by Asahi Kasei Pharma (AKP) and will be launched in Japan.

Ypsomed and i-SENS global partnership signing ceremony
Simon Michel , CEO Ypsomed and Geun Sig Cha, CEO i-SENS

Press Releases Ypsomed Group

Burgdorf – By entering into new partnerships and cooperations, Ypsomed has expanded its diabetes therapy offerings. With the goal of freedom of choice for the users of the mylife YpsoPump, the first study on the insulin pump with open interfaces as well as the connection to the therapy management solution diasend® by Glooko starts. In addition, Ypsomed launches the new blood glucose monitoring system mylife Aveo in spring 2020.